Literatur
- 1
Hach-Wunderle V, Kainer K, Krug B, Müller-Berghaus G, Pötsch P.
Heparin associated thrombosis despite normal platelet counts.
Lancet.
1994;
344
469-470
- 2 Hellstern P, Beeck H.
Zusammensetzung von Antithrombin-Konzentraten. In: Wellemann LS, Schinzel H (Hrsg) Antithrombin - Diagnostik und Therapie. Berlin,
Heidelberg, New York; Springer 1998: 127-128
- 3
Greinacher A, Zinn S, Wizeman U, Birk W.
Heparin-induced antibodies as a risk factor for thromboembolism and hemorrhage in
patients undergoing chronic hemodialysis.
Lancet.
1996;
348
764
- 4
Tardy-Poncet B, Tardy B, Reynaud J, Mahul P, Mismetti P, Mazet E, et al.
Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with
heparin-associated thrombocytopenia.
Chest.
1999;
115
1616-1620
- 5
Magnani H N.
Orgaran (danaparoid sodium) use in the syndrome of heparin-induced thrombocytopenia.
Proceedings of a workshop held in London on 1. Nov. 1996.
Platelets.
1996;
8
65-82
- 6 Magnani H N, Beijering R JR, Cate J W, Chong B H.
Orgaran anticoagulation for cardiopulmonary bypass in patients with heparin-induced
thrombocytopenia. In: Pifarré R (ed) New anticoagulants for the cardiovascular patient. Philadelphia,
PA; Hanley & Belfus Inc 1997: 487-500
- 7
Schmahl K S, Ganjoo A K, Harloff M G.
Orgaran (Org 10172) for cardiopulmonary bypass in heparin-induced thrombocytopenia:
role of adjunctive plasmapheresis.
J Cardiothor Vasc Anesthesia.
1997;
11
262-264
- 8
Greinacher A, Liebenhoff U, Kiefel V, Presek P, Mueller-Eckhardt C.
Heparin-associated thrombocytopenia: the effects of various intravenous IgG preoparations
on antibody mediated platelet activation - a possible new indication for high dose
i.v. IgG.
Thromb Haemost.
1994;
71
(5)
641-645
Dr. Stefan Seemann
Abteilung für Anästhesiologie und operative Intensivmedizin,
Allgemeines Krankenhaus Barmbek, 22291 Hamburg
